ISAR-REACT 5
2019
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
In 4,018 patients with acute coronary syndromes managed invasively, prasugrel reduced death, MI or stroke at one year compared with ticagrelor.
Result
Efficacy: Death, MI or stroke at 12 monthsHR 1.36
Below 1 favours ticagrelor, above 1 favours prasugrel.
- Absolute difference
- 2.4 points
The absolute difference is derived from the event rates.
Also reported: Major bleeding similar.
- Subtopic
- Antiplatelets
- Design
- Investigator-initiated, open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Schüpke S, et al. N Engl J Med. 2019;381(16):1524-1534.doi 10.1056/NEJMoa1908973
Discussion & critique
Open-label design and higher ticagrelor discontinuation drew criticism. Nonetheless shifted ESC preference towards prasugrel in NSTE-ACS without pre-treatment.